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Background
Specific subcutaneous immunotherapy (SCIT) with dust
mites is a proven effective procedure in the treatment of
allergic rhinitis (AR). However, there is concern about the
risk of adverse reactions, especially anaphylactic reactions.
The aim of this study was to evaluate the rate of adverse
reactions to SCIT with mites in patients with AR in
Allergy and Immunology Clinic.
Methods
We conducted a retrospective, longitudinal study evaluat-
ing patients with AR, over the age of three, who were
using SCIT with extracts of D pteronyssinus (Dp) and/or
B tropicalis (Bt) (FDA Allergenic). Data were collected
through interviews and medical records. The classification
of the severity of adverse reactions met the criteria estab-
lished by the Allergen Immunotherapy: a Practice Para-
meter Third Update (2011).
Results
100 patients with AR, aged between 3 and 64 (mean =
21.18, SD = 19.89), who received a total of 6,370 appli-
cations SCIT, were evaluated. The overall rate of adverse
reactions/applications was 0.09% (6), 0.06% (4) being
grade I and II. systemic reactions. Three systemic reac-
tions were immediate and one occurred 24 hours after
the application. The rate of local reactions/patient was
2% and systemic reactions/patient was 4%. Three
patients were using SCIT with Dp/Bt extract and 2 with
Dp extract. There was no relationship between the
phase of SCIT, association with asthma, severity of
rhinitis, serum IgE levels, sex or age with the occurrence
of adverse events (p> 0.05).
Conclusions
In this study, the rate of adverse reactions to SCIT with
mites in patients with AR was low, confirming the safety
of this procedure. No factor related to an increased risk
of adverse reactions was identified, probably due to the
small number (6) of observed adverse events observed.
The observation of a case of late systemic reaction indi-
cates the importance of counselling patients and care-
givers about this possibility.
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